Increased serum S100B protein in schizophrenia: a study in medication-free patients.
J Psychiatr Res
; 35(1): 11-4, 2001.
Article
in En
| MEDLINE
| ID: mdl-11287051
ABSTRACT
S100B protein, a calcium binding protein produced and released by glial cells, has been used as a sensitive marker of brain damage. Previous studies have found alterations in peripheral S100B levels in schizophrenic patients on medication. We compared serum S100B levels of 20 medication-free DSM-IV schizophrenic patients and 20 age-gender matched healthy controls. Schizophrenic patients presented higher serum S100B levels (mean 0.120 ng/ml+/-S.D. 0.140) compared to controls (mean 0.066 ng/ml+/-S.D. 0.067; P=0.014) and there was a negative correlation with illness duration (r=-0.496, P=0.031). The results of this study indicate that serum S100B levels may be a state marker of a limited neurodegenerative process, particularly in the early course of schizophrenia or, at least, in a subgroup of schizophrenic patients.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Schizophrenia
/
S100 Proteins
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Psychiatr Res
Year:
2001
Type:
Article
Affiliation country:
Brazil